Our strategies focus on developing new chemical entities for cancer and researching a new or better way to benefit patients.

Now we obtain several patents for 505(b)(1) and 505(b)(2).

Meanwhile, our team is researching the mechanism of anti-proliferation in tumors by repositioning the new indications of FDA-approved drugs which we obtained 505(b)(2) patents already.

The results provide advantages of those 505(b)(2) drugs as First-in-class medication in chemotherapy,shortening the development process and saving significant investment.

To increase the value and competitiveness of our products,our team is simultaneously developing new antiproliferative drug delivery,such as virus-like nanoparticles and nanoparticles.